TheBrief.Health
This review examines 7-year CROWN trial data showing lorlatinib’s unprecedented durability in ALK-positive NSCLC, highlighting survival gains, CNS protection, resistance suppression, and toxicity management.
Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity TheBrief.Health-yhteisöön!
Kokeilun jälkeen 7,99 € / kuukausi. · Peru milloin tahansa.
492 jaksot
RADIOS Consortium Explores Immune Effects of Cancer Checkpoint Therapy
The RADIOS consortium studies immune-related side effects of cancer immunotherapy, helping researchers improve treatment safety, personalize care, and optimize outcomes for patients receiving checkpoint inhibitors.
Physical Work Demands May Increase Autoimmune Rheumatic Risk
Physically demanding occupations may increase autoimmune disease risk in men, particularly inflammatory joint conditions, highlighting the importance of workplace prevention, early screening, and risk assessment.
Post-Bariatric Care: Beyond Surgery for Optimal Outcomes
Post-bariatric surgery success depends on consistent long-term care. Multidisciplinary follow-up helps prevent complications, supports mental and metabolic health, and sustains weight-loss outcomes.
Daily Activity Patterns May Forecast Mortality in Knee OA
Daily movement patterns may predict long-term health outcomes in people with knee osteoarthritis. Regular moderate activity supports symptom management, lowers mortality risk, and informs personalized care.
From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity TheBrief.Health-yhteisöön!